Insulin Pump Innovation: How Beta Bionics and Modular Medical Plan to Win the Diabetes Tech Race -( $BBNX $MODD )

Beta Bionics’ (BBNX) latest quarter reads like a reminder that in diabetes tech, algorithms can move revenue almost as quickly as they move insulin, while upstart Modular Medical (MODD) is quietly assembling a patch-pump beachhead a few exits earlier on the growth curve. One is already fine‑tuning a commercial bionic pancreas; the other is racing to make sure the ~$3 Billion “almost‑pumpers” market finally have a device that doesn’t require an engineering degree or a private equity stipend.

Beta Bionics steps on the gas

Beta Bionics turned in a robust third quarter, with revenue jumping as the iLet Bionic Pancreas rollout continued to scale and drove a sizable chunk of sales growth. The company reported thousands of new patient starts and a rapidly expanding installed base, enough to boost confidence and support raised full‑year guidance, even as profitability lagged the top‑line fireworks.

Behind the numbers sits the iLet, billed as the first FDA‑cleared insulin delivery system that autonomously calculates every dose using adaptive closed‑loop algorithms tied to continuous glucose monitoring. In practical terms, that means Beta Bionics is selling relief from carb counting and micromanagement—an attractive pitch in a market where mental bandwidth is as scarce as reimbursement dollars.

From lab vision to installed base

A decade ago, the iLet concept lived mostly in academic papers and conference posters; today it is a commercial system with tens of thousands of users and real‑world data to match. The company positions itself as a mission‑driven public benefit corporation, an origin story rooted in parents and patients that conveniently doubles as a moat when bidding for clinician mindshare.

Recent regulatory tweaks have been more evolutionary than revolutionary, including a Special 510(k) clearance that smoothed cartridge changes and pared back redundant low‑glucose alerts—small quality‑of‑life improvements that matter when devices are on 24/7. At the same time, Beta Bionics completed a glucagon pharmacokinetic and pharmacodynamic study in Canada and is planning a bihormonal feasibility trial in New Zealand, signaling that dual‑hormone automation remains part of the long‑term roadmap.

Modular Medical lines up its shot

While Beta Bionics optimizes autonomy, San Diego–based Modular Medical (MODD) is going after a different friction point: people with diabetes who would like a pump, but not an ecosystem. Its first‑generation MODD1 patch pump already has FDA clearance, and the company has now validated its production line and submitted its next‑generation Pivot tubeless patch pump for 510(k) review.

Pivot is designed as a two‑part, removable, 3‑milliliter patch pump that targets adults who want simplicity—wear it, take it off for a shower or a workout, and bolus without juggling a separate controller, while still retaining the data and connectivity expected of a modern electronic pump. Modular Medical has also secured Institutional Review Board approval to run an in‑house feasibility study using saline, an incremental but important step toward demonstrating extended wear and reliability before broad commercialization.

Different roads, same destination

The two companies are not exactly direct competitors so much as co‑authors of the same macro story: automated and wearable insulin delivery is carving out ever more of the $3‑plus billion patch‑pump and broader diabetes technology market. Beta Bionics is leaning into fully automated dose decisions and sophisticated algorithms for people ready to hand over the steering wheel, while Modular Medical is building a lower‑complexity, potentially lower‑cost tubeless patch pump for those still easing onto the on‑ramp.

If regulators cooperate, Modular Medical expects to be launch‑ready for Pivot in early 2026, just as Beta Bionics is broadening its installed base and advancing toward bihormonal capabilities—setting up a landscape where payers, clinicians, and patients will have to choose their flavor of “hands‑off” diabetes care. For investors, it is an industry where both fully autonomous bionic pancreases and minimalist patch pumps can win, provided they can convert clinical nuance into something Wall Street understands best: recurring revenue, subscription‑like supply sales, and a user base that would rather not go back to injections.

Modular Medical CEO Presenting at RSVP-Only Tribe Public CEO Dinner Event, Tuesday, Dec. 9 in Atlanta (Buckhead) – Seating Available..

Join an evening of candid diabetes innovation talk, great food, and high‑impact community building in Atlanta on Tuesday, December 9, from 6pm–8pm at The Capital Grille – Buckhead (private room), 255 East Paces Ferry Rd., 8th Floor, Atlanta, GA 30305. Tribe Public is hosting a corporate‑sponsored CEO Presentation and Q&A Dinner featuring James (“Jeb”) Besser, CEO of Modular Medical, Inc. (NASDAQ: MODD), to discuss “Pivot Patch Pump: Modular Medical’s Bid To Capture the $3B ‘Almost Pumper’ Diabetes Market.”

Seats are limited; if you would like to attend—or bring a friend, colleague, or family member with an interest in diabetes care innovation or medtech investing—please RSVP by emailing Events@TribePublic.com, and the team will do their best to accommodate. For more on Modular Medical, visit modular-medical.com, and to learn about future Tribe events or add to the “Wish List,” visit www.TribePublic.com.

About Tribe Public events

Tribe Public’s RSVP‑only, corporate‑sponsored CEO events are designed to give family offices, portfolio managers, accredited investors, business owners, and media direct access to company leadership in an intimate, community‑building setting over a complimentary dinner. These events are curated from the Tribe “Wish List” process, ensuring discussions focus on companies and themes investors and consumers have specifically requested

Beta Bionics steps on the gas

From lab vision to installed base

Modular Medical lines up its shot

Different roads, same destination

Modular Medical CEO Presenting at RSVP-Only Tribe Public CEO Dinner Event, Tuesday, Dec. 9 in Atlanta (Buckhead) – Seating Available..

The Sources…

You May Also Like

The InterGroup Corporation’s Hilton SF Stake Puts It at the Heart of San Francisco’s AI-Driven Revival – ( $AAPL $INTG $NVDA )

Steve Ballmer’s Intuit Dome Unveiled: $2 Billion HQ Redefines Sports Arenas and Corporate Campuses -( $INTU $MSFT $SPY )

Your Guide To Staying Informed In The Markets